Safety and Efficacy of AZD4547 in Combination With Fulvestrant vs. Fulvestrant Alone in ER+ Breast Cancer Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: FGFR Inhibition, Pharmacokinetics, Biomarkers|ER+ Breast Cancer
Interventions: DRUG: AZD4547|DRUG: Exemestane|DRUG: Placebo|DRUG: Fulvestrant
Sponsor: AstraZeneca